Category: Press Release

2020.05.20

I-Mab Expands Global Presence with New Hong Kong Office

2020.05.13

First Patient Dosed with I-Mab’s CD73 Antibody TJD5 in Phase 1/2 Clinical Trial in China for Advanced Solid Tumors

2020.04.29

I-Mab Filed 2019 Annual Report on Form 20-F

2020.04.28

I-Mab and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Trial of TJ202/MOR202 in r/r Multiple Myeloma in Mainland China

2020.04.24

Fighting COVID-19 together: What top medical experts from the US and China say

2020.04.24

I-Mab Announces Upcoming Participation at May Conferences

2020.04.03

I-Mab Announces IND Clearance from FDA for TJM2 to Treat Cytokine Release Syndrome (CRS) Associated with Severe Coronavirus Disease 19 (COVID-19)

2020.04.02

I-Mab Biopharma Announces First Patient Dosed in Phase 1/2a Clinical Trial of Anti-CD47 Antibody, TJC4, in China

2020.03.31

I-Mab Announces Financial Results for the Full Year Ended December 31, 2019, and Provides Corporate Update

2020.03.30

I-Mab Enters into Strategic Regional Partnership with Kalbe Genexine Biologics for Commercialization Rights of CD73 Antibody, TJD5, for Immuno-Oncology